These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 37577869)
1. Conventional Understanding of SARS-CoV-2 M Zhou K; Chen D Chembiochem; 2023 Nov; 24(22):e202300301. PubMed ID: 37577869 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. Kronenberger T; Laufer SA; Pillaiyar T Drug Discov Today; 2023 Jun; 28(6):103579. PubMed ID: 37028502 [TBL] [Abstract][Full Text] [Related]
3. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022. Pang X; Xu W; Liu Y; Li H; Chen L Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162 [TBL] [Abstract][Full Text] [Related]
5. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Martorana A; Gentile C; Lauria A Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574 [TBL] [Abstract][Full Text] [Related]
6. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
7. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
9. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265 [TBL] [Abstract][Full Text] [Related]
10. Progress of SARS-CoV-2 Main protease peptide-like inhibitors. Liu X; Ren X; Hua M; Liu F; Ren X; Sui C; Li Q; Luo F; Jiang Z; Xia Z; Chen J; Yang B Chem Biol Drug Des; 2024 Jan; 103(1):e14425. PubMed ID: 38082476 [TBL] [Abstract][Full Text] [Related]
11. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166 [TBL] [Abstract][Full Text] [Related]
13. Structure of M Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481 [TBL] [Abstract][Full Text] [Related]
14. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Goyal B; Goyal D ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186 [TBL] [Abstract][Full Text] [Related]
15. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19. Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441 [TBL] [Abstract][Full Text] [Related]
16. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
17. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509 [TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors. Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731 [No Abstract] [Full Text] [Related]
19. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
20. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]